NeuroSense Therapeutics L... (NRSNW)
NeuroSense Therapeutics Ltd. (NRSNW) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.13M |
| Beta | 1.60 |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -1.56 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 135 |
| Avg. Volume (20D) | |
| Open | 0.30 |
| Previous Close | 0.12 |
| Day's Range | 0.07 - 0.07 |
| 52-Week Range | 0.07 - 0.07 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NRSNW
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and ...
Financial Performance
In 2025, NeuroSense Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -11.13M, an increase of 8.96%.
Financial StatementsAnalyst Forecast
According to undefined analyst ratings, the average rating for NRSNW stock is "undefined". The 12-month stock price forecast is null, which is downside of 0% from the latest price.
Stock Forecasts